Recursion Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Recursion Pharmaceuticals has a total shareholder equity of $584.4M and total debt of $1.1M, which brings its debt-to-equity ratio to 0.2%. Its total assets and total liabilities are $775.9M and $191.4M respectively.
Key information
0.2%
Debt to equity ratio
US$1.11m
Debt
| Interest coverage ratio | n/a |
| Cash | US$474.34m |
| Equity | US$584.45m |
| Total liabilities | US$191.41m |
| Total assets | US$775.86m |
Recent financial health updates
Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely
Jan 31
We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth
Mar 01Recent updates
Recursion: AI Is Only As Good As The Data
Sep 11Recursion: Path Forward For REC-994 Remains Despite Mixed Response
Sep 04Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 12Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts
Aug 01Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery
Jun 24Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must
Jun 14Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%
May 22Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
Apr 10Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
Mar 20Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely
Jan 31Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress
Jan 12Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues
Dec 09What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today
May 09We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth
Mar 01Financial Position Analysis
Short Term Liabilities: RXRX's short term assets ($522.4M) exceed its short term liabilities ($86.1M).
Long Term Liabilities: RXRX's short term assets ($522.4M) exceed its long term liabilities ($105.3M).
Debt to Equity History and Analysis
Debt Level: RXRX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if RXRX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RXRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RXRX has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 39.8% each year.